LALPATHLAB2023-04-012023-06-30 LALPATHLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2023-06-30 LALPATHLAB2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539524 LALPATHLAB NOTLISTED Dr. Lal Path Labs Ltd. Equity 2023-04-01 2024-03-31 2023-07-27 2023-07-20 INR Millions First quarter 12:30:00 14:20:00 2023-07-27 2023-07-27 Not applicable Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2023-04-01 2023-06-30 Unaudited Standalone 4801000000.00 150000000.00 4951000000.00 990000000.00 0.00 0.00 898000000.00 73000000.00 184000000.00 1555000000.00 3700000000.00 1251000000.00 0.00 1251000000.00 359000000.00 -44000000.00 315000000.00 0.00 936000000.00 0.00 0.00 0.00 0.00 936000000.00 5000000.00 941000000.00 0.00 0.00 834000000.00 10 11.28 11.25 0.00 0.00 11.28 11.25 i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 27 July, 2023. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended June 30, 2023 and they have expressed an unmodified conclusion on the aforesaid results. ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iii. Figures for the quarter ended 31 March, 2023 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2022, which were subjected to limited review. iv. During the quarter ended 30 June, 2023, the Company has issued 41,000 equity shares of face value of Rs. 10 each on exercise of employee stock options. Subsequent to the quarter ended 30 June, 2023, the Company has issued 6,000 equity shares of face value of Rs. 10 each on exercise of employee stock options. v. The Board of Directors of the Company have approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023. The Board of Directors had approved final dividend of INR 6 per equity share (face value of INR 10 each) for the year ended 31 March, 2023. The same is subject to approval of shareholders at the ensuing Annual General Meeting. Due to size constraint, we have not pasted complete note to statement of financial results. Please refer pdf file for complete notes to the statement of Financial Results for the quarter ended June 30, 2023. Fees to collection centers/channel partners 706000000.00 Other expenses 849000000.00 Remeasurement of the defined benefit obligations 6000000.00 6000000.00 1000000.00 0.00